- Home
- ISOU vs ALLO Comparison
ISOU vs ALLO Comparison
Compare ISOU & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ISOU | ALLO |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Canada | United States |
| Employees | 24 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.3M | 707.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ISOU | ALLO |
|---|---|---|
| Price | $9.51 | $2.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $8.35 |
| AVG Volume (30 Days) | 120.5K | ★ 10.1M |
| Earning Date | 05-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $142,416.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.94 | $0.99 |
| 52 Week High | $13.58 | $4.46 |
Technical Indicators
Market Signals| Indicator | ISOU | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 56.97 |
| Support Level | $7.47 | $2.12 |
| Resistance Level | $10.27 | $2.36 |
| Average True Range (ATR) | 0.72 | 0.14 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 3.02 | 78.57 |
Price Performance
Historical ComparisonAbout ISOU IsoEnergy Ltd.
IsoEnergy Ltd is engaged in the acquisition, exploration, and evaluation of uranium properties in Canada. The company's project profile includes Geiger, Thorburn Lake, Full Moon, Edge, Collins Bay Extension, North Thorburn, 2Z Lake, and Madison. It operates in Canada, the United States, and Australia.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).